Company: SHPH
Filing Date: 2025-04-10
Form Type: PRER14A
Source: 0001641172-25-003635
Chunk: 45

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-04-10
Form: PRER14A
Chunk 45
---
 APPROVAL OF THE ISSUANCE OF IN EXCESS OF 19.99% OF OUR COMMON STOCK UPON CONVERSION OF THE CONVERTIBLE NOTES IN COMPLIANCE WITH NASDAQ LISTING RULE 5635(D).

| 31 |

Questions and Answers About the Meeting

Why am I receiving these materials?

You are receiving these materials because you were astockholder of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) as of March 13, 2025, which is the Record Date of our 2025 Annual Meeting of Stockholders. Our 2025 Annual Meeting of Stockholders will be held virtually on Friday, May 9, 2025 at www.virtualshareholdermeeting.com/SHPH2025.

What proposals will be voted on at the Annual Meeting and how does the Board of Directors recommend that i vote?

| PROPOSAL                                                                                                                           
 1: ELECTION OF DIRECTORS                                                                                                           |
| The                                                                                                                                
 Board of Directors recommends that you vote FOR each director nominee. These individuals bring a range of relevant experiences and 
 overall diversity of perspectives that is essential to good governance and leadership of our Company.                              |

| PROPOSAL                                                                                                                     
 3: EXECUTIVE COMPENSATION                                                                                                    |
| The                                                                                                                          
 Board of Directors recommends that you vote FOR approval of the Company’s executive compensation plan, on an advisory basis. 
 We believe the numbers that we have prepared are fair and in the best interest of the Company’s executives and stockholders. |

PROPOSAL 4: AUTHORIZATION OF THE BOARD OF DIRECTORS TO AMEND THE COMPANY’S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF ALL OF THE COMPANY’S ISSUED AND OUTSTANDING COMMON STOCK BY A RATIO IN THE RANGE OF 1-FOR-3 TO 1-FOR-10

The Board of Directors recommends that you vote FOR authorization of the Board of Directors to amend the Company’s amended and restated certificate of incorporation to effect the Reverse Stock Split of all of the Company’s issued and outstanding common stock by a ratio in the range of 1-for-3 to 1-for-10. We believe that conducting the Reverse Stock Split is in the best interest of the Company and its stockholders.

PROPOSAL 5: APPROVAL OF THE FIRST AMENDMENT TO THE SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 2018 EQUITY INCENTIVE PLAN TO INCREASE THE AMOUNT